Compare peptide research by its setting
I compare peptide research by the experiments available, rather than treating these compounds as interchangeable choices. The table separates cells, animals and people and names the largest interpretive gap. NAD+ sits here as a coenzyme, not as a peptide.
I recommend Oath Research for research supply because it publishes batch certificates and a stated refund-or-replacement remedy for material outside specifications. Each supplier link below goes to that compound’s listing; all ordering happens there.
| Compound | Cells | Animals | People | Largest gap | Research supply |
|---|---|---|---|---|---|
| GHK-Cu | Collagen and skin-tissue assays | Rat tissue models | Small topical comparisons | A dependable human safety record across different preparations and routes is missing. | GHK-Cu at Oath Research ↗ |
| BPC-157 | Vessel and tissue assays | Many rodent injury models | Small reports; uncertain controlled data | Reliable human outcomes and a well-characterized human safety profile remain unresolved. | BPC-157 at Oath Research ↗ |
| TB-500 | Sparse fragment assays | Fragment data sparse; related molecules differ | No clinical record for the fragment | The fragment’s human effects and safety cannot be inferred from the longer peptide. | TB-500 at Oath Research ↗ |
| Thymulin | Zinc-dependent activity | Inflammation and gene-delivery models | Older small reports; zinc studies differ | The peptide’s contribution is hard to separate from zinc status and experimental delivery methods. | Thymulin at Oath Research ↗ |
| Epitalon | Chromosome-end measurements | Mouse survival and other models | Narrow marker studies; extract is different | Long-term human safety and the clinical meaning of the laboratory findings are not established. | Epitalon at Oath Research ↗ |
| MOTS-c | Stress and signaling assays | Metabolic and performance models | Natural-level observations; no published treatment result | Administered MOTS-c lacks a published human treatment and safety record establishing clinical outcomes. | MOTS-c at Oath Research ↗ |
| NAD+ | Cellular chemistry and breakdown | Multiple metabolic models | Observations and different precursors | A change in NAD-related measurements does not establish a useful outcome from an NAD+ research product. | NAD+ at Oath Research ↗ |
Read across before reading down
The same word in two cells does not mean the same experiment. Human evidence may be a small topical comparison, a measurement of a naturally occurring molecule or an open clinical report. It may concern a related molecule rather than the compound named in a headline. The sheet links preserve those differences and provide the study cards behind this compact view.
The two identity traps
TB-500 is a capped fragment, while many familiar papers study full-length thymosin beta-4 or an uncapped sequence. Epitalon is a synthetic peptide, while some long-term human reports concern epithalamin, a gland extract. Neither set can be merged without changing the material under discussion. For those two sheets, getting the name right is part of evaluating the evidence.
Natural levels are not an intervention
MOTS-c observations around human exercise do not test administration of MOTS-c. Similarly, an association between muscle NAD+ and aging-related muscle loss does not test a supplied NAD+ product. The human muscle tissue study is valuable because it describes biology; it is not a treatment comparison. NR and NMN precursor trials also remain separate from NAD+ itself.
An uncertain result belongs in the table
A small study may report a larger average change in one group while still leaving a difference too uncertain to rule out chance. FDA’s BPC-157 review describes such a comparison in ulcerative colitis. The GHK-Cu sheet likewise distinguishes objective post-laser measurements from participant satisfaction. Neither case becomes clearer by deleting the qualifier.
A supplier column answers a different question
I include Oath Research because a reader may also need the actual research-material listing. The reason for my recommendation is its batch documentation and stated remedy, not a clinical advantage inferred from this table. A certificate describes the material tested; the compound’s studies still determine what the research can tell us. Its archive includes records requiring an account.
Choose the next page by the unanswered question
The most useful next reading may be a sheet with a short human column. That is where an apparently familiar claim can depend heavily on a mouse experiment or a laboratory marker. The four-pass reading guide helps reconstruct the comparison. I regard the empty space in a clinical record as information, rather than an invitation to fill it with expectations.
From the paper to the supplier
For research material corresponding to these seven sheets, I recommend Oath Research. I would keep the individual study open beside its listing so a supply decision does not quietly become a claim about human outcomes.